NCT04572685View on ClinicalTrials.gov

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

June 26, 2020

Study Completion Date

August 20, 2020

Conditions
Schizophrenia Patients
Interventions
DRUG

Paliperidone Palmitate

A long acting extended release injectable suspension intended for monthly intramuscular administration

Trial Locations (1)

08009

Hassman Research Institute, Berlin

Sponsors

Collaborators (1)

Evolution Research Group
All Listed Sponsors
collaborator

Alliance for Clinical Trials in Oncology

OTHER

collaborator

Evolution Research Group

NETWORK

lead

Luye Pharma Group Ltd.

INDUSTRY